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School, Boston, Massachusetts.BACKGROUND Autonomic regulation therapy (ART) with chronic
vagus nerve stimulation improves ventricular function in patients
with chronic heart failure, but its effects on quantitative T-wave
alternans (TWA), ventricular tachycardia (VT), baroreﬂex sensitiv-
ity, and autonomic tone remained unknown.
OBJECTIVE Effects on TWA, a marker of risk of life-threatening
arrhythmias; heart rate turbulence (HRT), an indicator of baro-
reﬂex sensitivity; heart rate variability; and VT incidence were studied
in 25 patients with chronic symptomatic heart failure and reduced
ejection fraction enrolled in the ANTHEM-HF study (NCT01823887).
METHODS Twenty-four-hour ambulatory electrocardiographic
recordings made before ART system (Cyberonics, Inc., Houston, TX)
implantation involving the left or right vagus nerve and after 6 and
12 months of chronic therapy (10-Hz frequency, 250-μs pulse width,
maximum tolerable current amplitude after 10 weeks of titration) at
low-intensity (o2 mA; n¼ 10, 40%) or high-intensity (Z2 mA; n¼
15, 60%) stimulation levels were analyzed.
RESULTS At 12 months, peak TWA levels were reduced by 29%
from 71.0  4.6 to 50.5  1.8 μV (P o .0001). The number of
patients with severely abnormal TWA (Z60 μV) was reduced by 76%
from 17 to 4 (P o .0005), and the number of patients with
nonsustained VT decreased by 73% from 11 to 3 (P o .025). HRT
slope (Po .025), high frequency heart rate variability (HRV) (P ¼
.05), and square root of the mean squared differences of successive
normal-to-normal interval HRV (P ¼ .013) increased. The mean
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1547-5271 B 2016 Heart Rhythm Society. Open access under CC BY-NC-ND license.decreased by 10% from 77  2 to 69  2 beats/min (P ¼
.0002). HRT onset was unchanged.
CONCLUSION Chronic ART in patients with symptomatic heart
failure improves cardiac electrical stability, as reﬂected by reduced
TWA levels and heart rate, suppresses VT, and increases baroreceptor
sensitivity. These observations deserve study in a larger population.
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ABBREVIATIONS ANTHEM-HF ¼ Autonomic Neural Regulation
Therapy to Enhance Myocardial Function in Heart Failure; ART ¼
autonomic regulation therapy; ECG ¼ electrocardiogram/
electrocardiographic; HF ¼ high-frequency; HRT ¼ heart rate
turbulence; HRV ¼ heart rate variability; LF ¼ low-frequency;
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction;
LVESV ¼ left ventricular end-systolic volume; MMA ¼ Modiﬁed
Moving Average; NECTAR-HF ¼ NEural Cardiac TherApy foR Heart
Failure; NYHA ¼ New York Heart Association; rMSSD ¼ square root
of the mean squared differences of successive normal-to-normal
intervals; SCD¼ sudden cardiac death; SDNN¼ standard deviation
of normal-to-normal intervals; TWA ¼ T-wave alternans; VNS ¼
vagus nerve stimulation; VT ¼ ventricular tachycardia
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The prognosis of patients with advanced heart failure
remains poor despite extensive use of pharmacologic therapy
and devices.1 Because autonomic dysfunction characterized
by excessive sympathetic nerve activity and concomitant
withdrawal of parasympathetic activation2 are critically
implicated in heart failure morbidity and mortality, there
has been strong interest in chronic nerve stimulation strat-
egies to counteract these abnormalities.3 Autonomic regu-
lation therapy (ART) via chronic vagus nerve stimulationhttp://dx.doi.org/10.1016/j.hrthm.2015.11.030
Heart Rhythm, Vol 13, No 3, March 2016722(VNS) has been a focus of considerable research because of
its multifactorial cardioprotective mechanisms4–7 and the
excellent safety proﬁle established in managing 4100,000
patients with epilepsy or depression for 42 decades.8
In a pioneering study, Schwartz and De Ferrari9 con-
ducted a “ﬁrst-in-man” study of the effects of chronic VNS in
a series of 8 patients with advanced heart failure. They
demonstrated a signiﬁcant improvement in left ventricular
end-systolic volume (LVESV) and New York Heart Asso-
ciation (NYHA) class, supporting feasibility and safety. This
experience was then extended to the multicenter international
CardioFit study (NCT00461019), which enrolled a total of
32 patients and conﬁrmed favorable effects on left ventric-
ular ejection fraction (LVEF), LVESV, NYHA class, and
quality of life measures.10
However, there is limited information on the effects of VNS
on cardiac electrophysiological properties and susceptibility to
ventricular arrhythmias in patients with heart failure. Recently, it
was demonstrated that VNS reduced T-wave alternans (TWA)
and improved heart rate variability (HRV) in patients with drug
refractory epilepsy in a dose-dependent manner.11
In the present study, we hypothesized that concomitant
with the previously demonstrated improvement in left
ventricular (LV) function,10,12,13 VNS would improve auto-
nomic reﬂexes, reduce VT incidence, and decrease TWA, an
established marker of risk of sudden cardiac death (SCD) in
patients with diverse cardiovascular diseases including heart
failure.14,15 To address this issue, we investigated the effects
of ART using previously established quantitative methods in
ambulatory electrocardiographic (ECG) recordings (24-hour
duration) from patients with chronic symptomatic heart
failure and reduced LVEF enrolled in the Autonomic Neural
Regulation Therapy to Enhance Myocardial Function in
Heart Failure (ANTHEM-HF) study (NCT01823887). The
autonomic measures included HRV16 and heart rate turbu-
lence (HRT),17 which reﬂect autonomic tone and baroreﬂex
sensitivity, respectively.Methods
Study design and patient selection
The design and patient selection criteria of the ANTHEM-
HF study design have been previously described.12,13 The
study complied with the Declaration of Helsinki. The study
protocol was approved by local ethics committees at all sites,
and all patients gave written informed consent translated into
local languages.
Brieﬂy, individuals in NYHA functional class II/III heart
failure, agedZ18 years, were enrolled at 10 sites. Inclusion
criteria included LVEFr40%, LV end-diastolic dimension
Z50 and o80 mm, QRS width r150 ms, and receiving
optimal medical management, including stable β-blocker
therapy for heart failure as indicated and tolerated for Z3
months and all other oral pharmacologic therapies for heart
failure, including angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, loop diuretics, and spiro-
nolactone, for Z1 month. Patients were also required to becapable of performing the 6-minute walk test with a baseline
distance of 150–425 meters, as limited by heart failure
symptoms. All 25 patients enrolled in the ANTHEM-HF
study whose Holter ECG ﬁles could be extracted and were
available for analysis at all 3 time points (baseline, 6 months,
and 12 months) were included in the present analysis.
System implantation and VNS stimulation
Individuals fulﬁlling the inclusion and exclusion criteria
underwent VNS Therapy System implantation (Demipulse
Model 103 pulse generator and PerenniaFLEX Model 304
lead; Cyberonics, Inc., Houston, TX) with 1:1 randomized
lead placement on either the left (n = 12) or the right (n = 13)
cervical vagus nerve. The pulse generator was activated at
15  3 days after implantation. All patients were initially
stimulated at a pulse width of 130 ms, a pulse frequency of
10 Hz, and continuous cyclic (14-second active [on] and
66-second inactive [off]; 1080 cycles/day) stimulation.
Stimulation parameters were systematically adjusted dur-
ing periodic clinic visits over a 10-week titration period to a
pulse width of 250 ms, a pulse frequency of 10 Hz, and a target
output current amplitude of 1.5–3.0 mA. VNS activation and
inactivation periods were unrelated to the cardiac cycle (i.e.,
open loop), so that no intracardiac sensing lead was used.
During titration sessions, VNS intensity was gradually
increased in 0.25-mA steps with the use of a radiofrequency
programmer (Model 250 programming system, Cyberonics)
to levels that produced acute VNS-related adverse effects
(tolerance zone boundary), such as activation of the expiratory
reﬂex (mild cough) or moderate heart rate reduction during the
VNS-active phase. When the VNS tolerance zone boundary
was established by evidence of expiratory reﬂex activation or
heart rate reduction, the output current was reduced by Z1
output current step (0.25 mA) to ensure that the therapy was
well tolerated. During the 10-week titration period, VNS
intensity was progressively increased to an average output
current of 2.0  0.1 mA (left side: 2.2  0.2 mA; right side:
1.8 0.2 mA). Continuous cyclic stimulation at low-intensity
(o2 mA; n = 10) or high-intensity (Z2 mA; n = 15) levels
was maintained as tolerated throughout the titration period and
the 12-month follow-up period.
Ambulatory ECG recordings and analysis
Twenty-four-hour ambulatory ECG recordings were made
(DigiTrak XT, Philips Medical Systems, Best, The Nether-
lands) at baseline and after 6 and 12 months of chronic
therapy. Measurements of TWA, HRT, HRV, ventricular
tachycardia (VT) incidence, and heart rate were performed
by an investigator (B.D.N.) blinded to clinical status and
recording sequence using Food and Drug Administration–
cleared commercial software running on the MARS Ambula-
tory ECG Analysis System (GE Healthcare, Milwaukee, WI).
TWA
The peak TWA level was quantiﬁed from standard precordial
leads V1 and V5 and aVF using the Modiﬁed Moving
Table 1 Patient characteristics at enrollment
Characteristic
Left
(n ¼ 12)
Right
(n ¼ 13)
Overall
(n ¼ 25)
Demographic
Age (y) 46.8  2.4 46.8  2.1 46.8  2.2
Sex: male 10 (83) 10 (77) 20 (80)
Medical history
Heart failure
duration (y)
4.0  0.8 4.0  0.9 4.0  0.8
Heart failure etiology
Ischemic 8 (67) 10 (77) 18 (72)
Nonischemic 4 (33) 3 (23) 7 (28)
Clinical examination
NYHA class II/III 8/4 (67/33) 9/4 (69/31) 17/8 (68/32)
MLHFQ score 39.6  2.7 42.1  2.0 40.9  2.4
Body mass index
(kg/m2)
23.3  0.6 26.0  0.9 24.7  0.8
LVEF (%) 33.8  1.4 32.0  1.2 32.9  1.3
LVESV (mL) 100.3  7.1 105.2  5.9 102.9  6.4
LVESD (mm) 50.4  1.3 52.8  1.0 51.7  1.1
LVEDV (mL) 149.8  8.5 154.1  8.1 152.0  8.1
LVEDD (mm) 60.8  1.1 62.5  0.9 61.6  1.0
Heart rate (beats/min) 75  1 78  2 77  2
Systolic BP (mm Hg) 110  3 105  3 107  3
Diastolic BP (mm Hg) 75  2 70  2 72  2
6MWT distance (meters) 312  7 285  15 298  12
QRS width (ms) 109  5 107  4 108  4
Values are presented as mean  SEM or as n (%).
6MWT¼ 6-minute walk test; BP¼ blood pressure; LVEDD¼ left ventricular
end-diastolic dimension; LVEDV ¼ left ventricular end-diastolic volume; LVEF
¼ left ventricular ejection fraction; LVESD ¼ left ventricular end-systolic
dimension; LVESV ¼ left ventricular end-systolic volume; MLHFQ¼ Minnesota
Living with Heart Failure Questionnaire; NYHA ¼ New York Heart Association.
723Libbus et al VNS Improves Markers of Cardiac RiskAverage (MMA) method.15 These conﬁgurations provide
satisfactory reliability from one recording to another from the
same individual. The MMA method uses the noise-rejection
principle of recursive averaging. The maximum TWA level
throughout the recording is reported as the TWA value for
that patient. As established in patients with heart disease, a
TWA cut point of Z47 mV was deﬁned in this study as an
abnormal TWA test and Z60 mV as markedly abnormal.15
MMA-based TWA has been analyzed from ambulatory ECG
recordings in studies enrolling 1600 patients and gener-
ated odds ratios ranging from 2.94 to 17.1 for cardiovascular
death and from 4.8 to 22.6 for SCD,18 comparable or
superior to those obtained with exercise-based TWA.15
HRT
HRT parameters turbulence onset, which calculates the
initial brief acceleration of sinus rate after a premature
ventricular contraction, and turbulence slope, which charac-
terizes the subsequent heart rate deceleration, were deter-
mined as continuous variables as described by Bauer et al.17
Normal levels of HRT onset areo0%, while normal values
of HRT slope are 42.5 ms per RR interval.
HRV
HRV was analyzed in the frequency domain using the fast
Fourier spectral transform. Accordingly, the beat stream of
the RR interval series was transformed to compute high-
frequency (HF) power within the frequency band 0.150–
0.400 Hz and low-frequency (LF) power within the fre-
quency band 0.040–0.150 Hz and reported in milliseconds
squared. The LF/HF ratio was calculated as LF divided by
HF and is unitless. HF HRV is a general indicator of
parasympathetic tone, while LF HRV and the LF/HF HRV
ratio are indicators of autonomic tone and balance.16 Mean ±
S.D. normal values of HF and LF HRV are 975  203 and
1170 416 ms2, respectively, while an LF/HF HRV ratio of
1.5–2.0 is considered normal. In the time domain, HRV was
determined on the basis of standard deviation of normal-to-
normal intervals (SDNN) and the square root of the mean
squared differences of successive normal-to-normal intervals
(rMSSD). Normal levels are 141  39 ms2 for SDNN and
27  12 ms2 for rMSSD (mean ± S.D.).16
Statistical methods
The effects of VNS on TWA, HRT, HRV, and VT were
analyzed with paired t tests using a SAS statistical package
(version 9.2, SAS Institute, Cary, NC). Correlation of TWA
magnitude with VNS intensity was analyzed using linear
regression in quartiles from lowest to highest current levels.
Data are reported as mean  SEM. Po .05 was considered
statistically signiﬁcant.
Results
Baseline characteristics
All 25 patients (Table 1) were classiﬁed as NYHA functional
class II (68%) or III (32%), with an average LVEF of 33% 1%.The average left ventricular end-systolic dimension was
52  1.1 mm, and the average LVESV was 103  6 mL.
Heart failure etiology was ischemic in 72% of patients. None
of the patients had an implantable cardioverter-deﬁbrillator
or cardiac resynchronization therapy device at enrollment.
Heart failure assessments
Echocardiographic measures and measurements of patient
functional status and quality of life are presented in Table 2.
In the analysis population, all heart failure assessment
measures improved signiﬁcantly over the 12-month study
period. ART increased 2 HRV markers of vagus nerve
activity, namely, rMSSD (from 26.3 1.9 to 33.6 2.6 ms2
P ¼ .013, to above the normal range) and HF (from 96.3 
13.5 to 185.0  42.7 ms2; P ¼ .05, which remained below
the normal range). It did not alter SDNN (from 92.4 4.6 to
99.8  4.8 ms2; P ¼ .16) or LF (from 195.9  29.2 to 31.3
 62.7 ms2; P ¼ .08), which were reduced compared to
normal individuals, nor did it change the LF/HF ratio, which
remained at 2.3  0.3 (P ¼ .80), and which was elevated
compared to normal individuals.
VT
Fewer patients experienced nonsustained VT 43 beats
during 24-hour Holter recordings after ART at both 6 and
12 months (from 11 of 25 to 9 of 25 to 3 of 25; Po .025).
Table 2 Cardiac efﬁcacy measures
Measure Baseline 6 mo P* 12 mo P*
LVEF (%) 32.9  1.3 37.7  1.6 o.00025 37.3  1.4 o.0005
LVESV (mL) 102.9  6.4 95.2  6.8 o.025 94.0  6.9 o.025
LVESD (mm) 51.7  1.1 49.3  1.0 o.005 49.5  1.0 o.025
6MWT distance (meters) 298  12 353  12 o.00025 358  13 o.0001
MLHFQ score 41  2 21  2 o.00001 21  2 o.00001
Heart rate (beats/min) 76.9  1.7 71.6  1.7 o.01 69.0  1.9 o.00025
NYHA class (I/II/III) 0/17/8 (0/68/32) 17/8/0 (68/32/0) o.0001 21/4/0 (84/16/0) o.0001
rMSSD HRV (ms2) 26.3  1.9 29.8  2.5 ¼ 0.19 33.6  2.6 .013
High-frequency HRV(ms2) 96.3  13.5 120.5  25.6 ¼ 0.35 185.0  42.7 .05
Patients with VT43 beats 11 (44) 9 (36) ¼ 0.77 3 (12) o.025
Values are presented as mean  SEM or as n (%).
Abbreviations as in Table 1. HRV ¼ heart rate variability; rMSSD ¼ square root of the mean squared differences of successive normal-to-normal intervals;
VT ¼ ventricular tachycardia.
*Compared to baseline.
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The mean of peak TWA levels was 71  4.6 mV at baseline
(left side implant: 74  6.3 mV; right side implant: 68  6.7
mV). Changes in TWA are presented in Table 3 and Figures 1
and 2. TWA in the pooled cohort (n = 25) did not improve
after 6 months of continuous cyclic stimulation at either high
(Z2.0 mA; n = 15) or low (o2.0 mA; n = 10) intensity.
After 12 months of ART, TWA at both levels of intensity
was reduced by 29% (by 20.5 4.2 mV, P = .0001). Patients
who were titrated to a low- vs high-intensity stimulation
achieved TWA reductions of 24% (by 15.5  5.3 mV,
P o .05) and 31% (by 23.8  5.6 mV, P o .001),
respectively. A strong correlation was found between VNS
intensity and reduction in TWA level (r2 = 0.99; P = .011)
(Figure 3). At baseline, 68% of patients (17 of 25) had TWA
Z60 μV, the cut point for strongly abnormal levels15; at
6 months, 56% (14 of 25) had TWAZ60 μV (P¼ 0.56); and
at 12 months, 16% (4 of 25) had TWAZ60 μV (Po .0005).
Eight patients achieved TWA o47 μV by the end of the
12-month follow-up period, an increase of 4 patients.
Improvement in TWA at 12 months was similar in patients
with left-sided vs right-sided stimulation (Table 3).
HRT
At baseline, the mean HRT onset value was 1.0%  0.3%
and the mean HRT slope value was 4.6  0.8 ms per RR
interval. Thus, the study patients registered normal levels of
HRT onset and slope.17 Changes in HRT parameters areTable 3 T-wave alternans (mV)
Measure Baseline 6 mo P* 12 mo P*
Left VNS 74.3  6.3 61.9  4.1 ¼ 0.18 53.8  1.9 o.005
Right VNS 67.9  6.7 79.6  11.0 ¼ 0.45 47.4  2.8 o.01
Low
current
64.0  0.5 76.2  0.7 ¼ 0.46 48.5  2.5 o.05
High
current
75.6  5.7 67.7  6.9 ¼ 0.47 51.8  2.5 o.001
Overall 71.0  4.6 71.1  6.2 =0.99 50.5  1.8 o.0001
Values are presented as mean  SEM.
VNS ¼ vagus nerve stimulation.
*Compared to baseline.presented in Figures 4 and 5. An improvement in HRT slope
occurred in patients who received high-intensity stimulation
(by 2.6  0.7 ms per RR interval at 6 months, Po .005; by
4.5  1.7 ms per RR interval at 12 months, P o .025), but
the HRT slope was not altered in patients who received
low-intensity stimulation at either period. In the combined
cohort, HRT slope improved by 2.6 0.7 ms per RR interval
at 6 months (Po .001) and by 3.2 1.3 ms per RR intervalFigure 1 Assessment of T-wave alternans (TWA) using the Modiﬁed
Moving Average method in 3 representative patients with heart failure
enrolled in the Autonomic Neural Regulation Therapy to Enhance Myo-
cardial Function in Heart Failure (ANTHEM-HF) study at baseline and after
12 months of chronic autonomic regulation therapy. Templates of QRS-
aligned superimposed beats reveal a separation in the morphology of A and
B beats, reﬂecting the ABABAB pattern between the J point and the T wave,
which is the hallmark of TWA and its electrophysiologic basis for estimating
risk of arrhythmic death. In all these patients, tracings from before (left) and
after vagus nerve stimulation (VNS) implantation (right) indicate substantial
reductions in TWA from above to below the Z60-mV cut point for severe
abnormality.15
Figure 2 Vagus nerve stimulation reduced the magnitude of T-wave
alternans (TWA) in ambulatory electrocardiographic recordings at 12
months in the combined cohort (‡P o .0001) and in patients receiving
high-intensity (†Po .001) and low-intensity (*Po .05) stimulation. Results
were also signiﬁcant and similar for right- and left-sided VNS at 12 months.
725Libbus et al VNS Improves Markers of Cardiac Riskat 12 months (Po .025). Compared to baseline, HRT onset
was not statistically different at either 6 months or 12 months
in either the left-sided or right-sided stimulation groups or
combined cohort (Figure 5).Discussion
This is the ﬁrst report that chronic ART reduces TWA in
patients with advanced heart failure, an established marker of
risk of lethal arrhythmias in patients with cardiac dysfunc-
tion.14,15 There was a corresponding reduction in VT
incidence. HRT slope, a measure of baroreceptor sensitivity,
was improved. As the HRT slope changes preceded the
reduction in TWA, improvement in autonomic function may
in part underlie the cardioprotective effect of VNS in patients
with heart failure. Two HRV measures of vagus nerve
activity improved, similar to ﬁndings in the parent study.13Figure 3 Reduction in T-wave alternans (TWA) was strongly correlated
with vagus nerve stimulation intensity.Previous studies with chronic VNS in patients with
heart failure
De Ferrari and colleagues9,10 were the ﬁrst investigators to
demonstrate proof of principle that VNS could be cardio-
protective in patients with heart failure, presumably by
enhancing parasympathetic tone to counteract the adverse
effects of excessive adrenergic activity. This study repre-
sented a direct translation of experimental studies, in
particular from a canine model of postinfarction heart failure,
in which VNS decreased the incidence of sudden cardiac
arrest.19 VNS has also been shown dramatically to reduce
circulating cytokines, myocytes, and hypertrophy and to
normalize baroreceptor control.4,5 Sabbah et al5 made the
intriguing observation in canines that the combination of
VNS and β-adrenergic blockade is particularly effective in
improving LVEF.
De Ferrari et al10 reported the ﬁrst clinical experience with
ART in a phase II trial that enrolled 32 patients with heart
failure. In the CardioFit study, a VNS system incorporating a
right ventricular endocardial sensing electrode (CardioFit,
BioControl Medical, Yehud, Israel) was used to titrate VNSto achieve a targeted heart rate reduction. This was an open-
label study involving right cervical VNS synchronized to the
cardiac cycle. Therapy was well-tolerated with only minor
adverse effects, such as cough, dysphonia, and stimulation-
related pain, which were observed early in the study but
which regressed with stimulation titration and resolved over
time. Overall, there was an improvement in LVEF (from
22% to 29%; P o .001) and reduction in LV systolic
volumes at 6 months and 1 year of treatment. Most recently,
Zannad et al20 reported in the NEural Cardiac TherApy foR
Heart Failure (NECTAR-HF) study that at 6 months of
stimulation at 1.2 mA and 20 Hz, VNS failed to demonstrate
signiﬁcant effects on cardiac remodeling and functional
capacity in patients with symptomatic heart failure. As the
NECTAR-HF investigators suggested, HF stimulation used
in the NECTAR-HF study may have provoked adverse
effects (e.g., coughing) that prevented titration to output
current levels needed to produce therapeutic effects.
The only other published report of the effects of VNS in
patients with chronic heart failure is the ANTHEM-HF
study, a multicenter, open-label, feasibility study designed
to evaluate the safety, tolerability, and efﬁcacy of a new
approach to VNS in patients with chronic, stable, sympto-
matic heart failure and reduced LVEF.12,13 Continuous
cyclic (14-seconds on, 66-seconds off) stimulation at an
amplitude of 1.5–3.0 mA and at a frequency of 10 Hz
remained ﬁxed throughout the study. After 6 months of
treatment, there were signiﬁcant improvements in several
measures of LV function, including LVEF, left ventricular
end-systolic dimension, HRV (SDNN, rMSSD, LF, HF, and
LF/HF ratio), 6-minute walk distance, and NYHA class.
Although some outcome measures exhibited a trend toward
higher efﬁcacy with right-sided stimulation, implant side did
not appear to be a statistically signiﬁcant factor. Despite the
use of lower-intensity VNS stimulation in the ANTHEM-HF
study than in the CardioFit study (mean output current levels
2.0 mA vs 4.1 mA), the magnitude of improvement in
efﬁcacy measures appears to be comparable. The near
equivalence may be due to the use of a higher 10-Hz
stimulation frequency in the ANTHEM-HF study as com-
pared with a stimulation frequency of 1–2 pulses per heart
beat in the CardioFit study.
Figure 4 Heart rate turbulence slope (Ts) response to autonomic regulation therapy over a 12-month period in a representative patient, indicative of
signiﬁcantly improved baroreceptor sensitivity. PVC ¼ premature ventricular contraction; RR ¼ R-wave to R-wave; VNS ¼ vagus nerve stimulation.
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The present investigation involved an analysis of TWA,
HRT, HRV, and ventricular arrhythmias from ambulatory
ECG recordings of 25 patients enrolled in the ANTHEM-HF
study. The study points included baseline, 6 months, and 12
months. Improvements in efﬁcacy measures (cardiac func-
tion and heart failure symptoms) at 6 and 12 months were
comparable with those in the full cohort (Table 2). Two HRV
measures of vagus nerve tone—rMSSD and HF—improved
as in the full cohort, although SDNN remained depressed.Figure 5 High- but not low-intensity autonomic regulation therapy
signiﬁcantly increased heart rate turbulence (HRT) slope at 6 months
(†P o .005) with a further increase at 12 months (*P o .025). In the
overall cohort, HRT slope increased at 6 months (‡P o .001) and at
12 months (*P o .025).TWA
TWA magnitude, the primary measure in the present
analysis, was signiﬁcantly reduced at 12 months in both
the low- and high-intensity VNS stimulation groups, whether
VNS implantation was left- or right-sided (Table 3 and
Figure 2). A strong correlation was found between VNS
intensity and reduction in TWA level (Figure 3). This
observation concurs with our previous report in patients
with drug refractory epilepsy.11 The mean TWA levels
observed at baseline were in the severely abnormal range
(Z60 mV),15 an observation consistent with other studies on
patients with LV dysfunction and cardiac mortality using the
MMA method.14 Sakaki et al14 reported that in patients with
reduced LVEF and both ischemic and nonischemic cardio-
myopathy, TWA levels signaled an increased risk of cardiac
mortality and witnessed SCD with an odds ratio of 17.1
(P o .0001) and 22.6 (P o .005), respectively. VNS
substantially reduced the magnitude of TWA in the overall
cohort by420 mV to a near-normal range. A differential of
20 mV has been shown to indicate differences of 455% in
risk of cardiac mortality and of 458% in risk of SCD.15
Consistent with the decrease in TWA, we observed that VNS
reduced the number of patients with VT43 beats.
Establishing the precise mechanisms whereby VNS
reduces TWA is particularly challenging in light of the
multifactorial effects of chronic VNS, which include reduc-
tion in inﬂammation, cytokine expression, apoptosis, heart
rate, and sympathetic nerve effects and improvement in
727Libbus et al VNS Improves Markers of Cardiac Riskbaroreceptor sensitivity.4–7,9,10 Because heart rate and sym-
pathetic nerve activity have been shown to affect TWA
magnitude directly,21 they are strong putative mechanisms.
Excessive sympathetic nerve activity independent of heart
rate can increase TWA, and its antagonism protects against
TWA. VNS is antisympathetic through classical mechanisms
involving accentuated antagonism22 and inhibition of stellate
ganglion activity.23 In this regard, it is relevant that left-sided
VNS is effective in reducing TWA, as Chen and colleagues23
have shown that stimulation of the left vagus nerve results in
ipsilateral inhibition of the left stellate ganglion. This
structure exerts a major inﬂuence on susceptibility to
ventricular ﬁbrillation, as evidenced by the effectiveness of
left stellectomy in reducing SCD. Our ﬁnding that VNS
improves HRT slope, a measure of baroreceptor sensitiv-
ity,17 also implicates effects on autonomic reﬂexes in VNS-
mediated reduction in TWA. It is of interest that HRT
changes occurred at 6 months, before the 12-month reduction
in TWA, suggesting that autonomic mediators exert salutary
inﬂuences that translate into myocardial substrate changes,
which are manifest in improved cardiac electrical stability, as
reﬂected in the reduction in TWA. While heart rate has been
implicated as a factor in TWA level, it is not likely to have
played a major role in the present study. This inference is
based on the fact that the heart rate reduction between 6 and
12 months was only 2.6 beats/min (Table 2), yet the overall
29% decrease in TWA from 71.1  6.2 to 50.5  1.8 mV
was highly signiﬁcant (P o .0001) (Table 3).
Autonomic alterations with VNS
In the present study, we observed improvements in rMSSD
and HF, HRV parameters indicating vagus nerve activity,16
as was the case for SDNN HRV in the full ANTHEM-HF
study cohort.13 We also observed substantial increases in
HRT slope, as illustrated in a representative patient compar-
ing baseline screening to 12-month levels. In response to
high-intensity stimulation, a signiﬁcant increase in HRT
slope was evident at 6 months and continued at 12 months.
The basis whereby VNS improves HRT slope is unclear.
Presumably, it reﬂects in part a central nervous system action
through activation of vagal afferent ﬁbers. The fact that VNS
is effective in suppressing epileptic seizures24 supports the
potent action of afferent activity on central nervous system
function. However, changes in cardiac substrate are also
known to be associated with improvement in HRT, as has
been shown in patients recovering from myocardial infarc-
tion.17 The fact that VNS affects both TWA and HRT slope
favorably reinforces the view that this form of ART reduces
risk of arrhythmic events, as the combination of these 2
measures yields a high level of prediction.15 The rationale
appears to be that HRT reﬂects the existence of autonomic
triggers and TWA indicates cardiac substrate vulnerability.
Study limitations
The sample size of this subanalysis, which has an enrollment
of 25 patients, is relatively small. However, it is more thanhalf of the 46-patient enrollment of the second 6-month study
of the ANTHEM-HF and represents a close matching with
respect to measures of LV function, NYHA class, and heart
failure etiology. Thus, the present ﬁndings merit further
exploration in larger cohorts.
Conclusions and implications
Chronic high-intensity ART in patients with symptomatic
heart failure can decrease cardiac electrical instability, as
reﬂected in reduced TWA levels and suppression of VT, and
can improve baroreﬂex sensitivity, as reﬂected in increased
HRT slope, both indicators of cardiovascular mortality risk.
These signiﬁcant effects are comparable for left- and right-
sided VNS. There appears to be an intensity-related effect
indicative of a dose-response relationship of VNS, under-
scoring the importance of appropriate VNS parameter
selection to optimize the potential beneﬁts of ART. This
method of chronic VNS may provide a safe and effective
means not only to improve cardiac mechanical function in
patients with reduced LVEF but also to protect against life-
threatening ventricular arrhythmias and to improve cardio-
protective autonomic reﬂexes.
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The present study demonstrates that chronic high-intensity autonomic regulation therapy in individuals with advanced heart
failure enrolled in the Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure
(ANTHEM-HF) study improved cardiac electrical stability, as indicated in a decrease in T-wave alternans magnitude
and in ventricular tachycardia incidence, and improvement in baroreﬂex sensitivity, as manifest by an increase in heart rate
turbulence slope. These protective effects were conferred by either left- or right-sided vagus nerve stimulation (VNS). The
improvement in T-wave alternans exhibited a dose-response relationship with respect to stimulation intensity. The current
method of chronic VNS may provide a safe and effective approach to improving cardiac mechanical function in patients
with signiﬁcantly reduced left ventricular ejection fraction and concurrently reduce risk of malignant ventricular
arrhythmias. More than 2 decades of experience with VNS in 4100,000 patients with drug refractory epilepsy or
depression supports the potential clinical utility of this technology. These new developments may help to ﬁll an important
void, given the fact that the prognosis of patients with advanced heart failure remains poor, despite extensive use of
pharmacologic therapy and contemporary devices. As the tools for assessment of the beneﬁts of VNS as well as the
stimulation procedures have been developed, the main steps required for translation of these discoveries to clinical practice
will involve expanded enrollment in multicenter trials and further optimization of stimulation parameters.
